NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
Fate Therapeutics
First Affiliated Hospital of Wenzhou Medical University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins